the following is a reminder of the 3 Million goal in its context-somebody else could also post the recent update early October? re the UK partner firm to help provide the larger context
re 'non-affilated MD's' somebody removed the word and context of 'not affillated with NNLX'-does not mean the MD's are not affillated with other companies-they could be affiliated with other companies
in any partnership, a small startup like NNLX will be the junior partner and NDA's will be dictated by the larger companies who are associated with NNLX, past and present. Such prevent NNLX from revealing the partners identity etc -past or future- until such time a product is ready for public unveiling-and NNLX usually must get such partners approval for updates or PR's
if NNLX violates an NDA, NNLX can spend its time fighting the lawsuit and hence go bankrupt instead of proceeding with its development efforts - and no further company interested in NDA's would contract with NNLX
as I've noted before the obsession with secrecy in certain fields -especially bio/pharma- can exceed that of governments
I've also noted that even SEC reporting bio and pharma companies -in their SEC reportings- will sometimes note that the contents of the reporting will be secret to all (except the necessary SEC personnel) either for a stated period or indefinitely- that is not unusual- put this into the context of the Russians and Chinese stealing literally trillions of USA tech/research and development to better compete with and eventually confront the USA on the battlefield etc
PUBLIC institutional investors usually cannot invest in a company that is not SEC reporting- due to the requirements of fiduciary duty
PRIVATE institutional investors and semi private or quasi-institutional investors-such as hedge funds-can generally invest where they want- as long as the private members are informed of the funds investing strategy involved
Posted On: 08/21/2019 6:53:03 AM
Posted By: willtheoak
like a sleeping purple dinosaur, nanologix has awakened
NanoLogix Seeks $3 Million For Expansion and Development
Offers Net-Revenue Share of N-Assay Bacteria Diagnostic
NanoLogix is discussing with domestic and international investment groups, and is seeking additional interested parties, for an investment offer of a net-revenue interest share of the N-Assay Bacteria Diagnostic and its planned associated Pretest. In exchange for an investment of up to $3 million, NanoLogix proposes a five-year 3-5% net-revenue sharing arrangement beginning with the proposed marketing rollout of the N-Assay in 2021, following planned patient studies in Houston. The funds are to be used for company expansion, development, production and marketing for the N-Assay, Pretest, and FlatPack petri plate technologies. There is no stock issuance or dilution involved with the funding proposal.
A PowerPoint presentation on the N-Assay Bacteria Diagnostic is included to illustrate just some of the advantages of the technology. The PowerPoint includes information on upper respiratory infections (URI), general sepsis infections, and sepsis infections related to infant low-birth weights. In future updates there will be information on shares of the diagnostic market devoted to each of those, and other infections for which configurations of the N-Assay are being explored.